Literature DB >> 26047368

Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.

Eric I Marks1, Matthew Brennan, Wafik S El-Deiry.   

Abstract

We present the case of a 62-year-old-man with moderately differentiated adenocarcinoma of the rectum. This patient underwent neoadjuvant chemoradiation and surgical resection followed by adjuvant chemotherapy. After completing therapy, this patient had 2 instances of CEA elevation, both of which preceded the discovery of recurrent disease. While on treatment for these recurrences, CA 19-9 increased rapidly to 4,405. This CA 19-9 elevation persisted for approximately 4 months in the absence of clinical, radiographic or additional serologic evidence of progressive disease before returning to baseline. Shortly after this tumor marker normalized, a small area of locally recurrent disease was discovered. This case highlights the utility and pitfalls of colorectal cancer disease monitoring with CEA and CA 19-9. The differential diagnosis of CA 19-9 elevation is discussed in this report.

Entities:  

Keywords:  CA 19-9; CEA; metastatic colorectal adenocarcinoma; tumor marker

Mesh:

Substances:

Year:  2015        PMID: 26047368      PMCID: PMC4622690          DOI: 10.1080/15384047.2015.1057360

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  31 in total

1.  Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases.

Authors:  Raphael L C Araujo; Mithat Gönen; Peter Allen; Ronald DeMatteo; Peter Kingham; William Jarnagin; Michael D'Angelica; Yuman Fong
Journal:  Ann Surg Oncol       Date:  2015-01-13       Impact factor: 5.344

2.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Authors:  M A Tempero; E Uchida; H Takasaki; D A Burnett; Z Steplewski; P M Pour
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

Review 3.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

Review 4.  Role of tumour markers, cytogenetics.

Authors:  R Lamerz
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

5.  The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy.

Authors:  M Tampellini; A Ottone; I Alabiso; C Baratelli; L Forti; A Berruti; E Aroasio; G V Scagliotti
Journal:  Tumour Biol       Date:  2014-11-06

6.  Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma.

Authors:  J P Arnaud; C Koehl; M Adloff
Journal:  Dis Colon Rectum       Date:  1980-04       Impact factor: 4.585

7.  Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.

Authors:  Meltem Caglar; Can Yener; Erdem Karabulut
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-09-12       Impact factor: 2.924

8.  The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer.

Authors:  J L McCall; R B Black; C A Rich; J R Harvey; R A Baker; J M Watts; J Toouli
Journal:  Dis Colon Rectum       Date:  1994-09       Impact factor: 4.585

Review 9.  The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis.

Authors:  Konstantinos A Paschos; David Canovas; Nigel C Bird
Journal:  Cell Signal       Date:  2009-01-07       Impact factor: 4.315

10.  First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs.

Authors:  Yutaka J Kawamura; Aika Tokumitsu; Ken Mizokami; Junichi Sasaki; Shingo Tsujinaka; Fumio Konishi
Journal:  Clin Colorectal Cancer       Date:  2010-01       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.